본문 바로가기

Oncolytic Vaccinia Virus in Lung Cancer Vaccines

문서 유형
연구출판물 · 리뷰논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q2
저널
VACCINES10(2) · 2022
피인용
Web of Science 28Scopus 31
FWCI (Scopus)
0.95
JCR IF
JCR 2021 4.961
ISSN
2076-393X

저자

  1. 카오상 트루엉제1저자Pusan Natl Univ, BIO IT Foundry Technol Inst, Busan 46241, South Korea
  2. 유소영교신저자Pusan Natl Univ, BIO IT Foundry Technol Inst, Busan 46241, South Korea

초록

© 2022 by the authors. Licensee MDPI, Basel, Switzerland.Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tu-mor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising cancer treatment option for effective cancer immunotherapy and thus can also be utilized in cancer vac-cines. Non-small cell lung cancer (NSCLC) is likely to respond to immunotherapy, such as immune checkpoint inhibitors or cancer vaccines, since it has a high tumor mutational burden. In this re-view, we will summarize recent applications of VV in lung cancer treatment and discuss the potential and direction of VV-based therapeutic vaccines.

키워드

Cancer vaccineImmunotherapyNon-small cell lung cancerOncolytic virusPersonalized vaccinationVaccinia virusSWITCH MAINTENANCE THERAPYGROWTH-FACTOR VACCINETUMOR CELL VACCINEPHASE-II TRIALBELAGENPUMATUCEL-L1ST-LINE CHEMOTHERAPYCLINICAL-TRIALDOUBLE-BLINDCIMAVAX-EGFIMMUNOTHERAPY

식별자

Scopus EID
2-s2.0-85124016869
WoS UID
000762040200001